

# Identification of an infectious progenitor for the multiple-copy HERV-K human endogenous retroelements

Marie Dewannieux,<sup>1,3</sup> Francis Harper,<sup>2,4</sup> Aurélien Richaud,<sup>1,4</sup> Claire Letzelter,<sup>1</sup> David Ribet,<sup>1</sup> Gérard Pierron,<sup>2</sup> and Thierry Heidmann<sup>1,5</sup>

<sup>1</sup>Unité des Rétrovirus Endogènes et Éléments Rétroïdes des Eucaryotes Supérieurs, UMR 8122 CNRS, Institut Gustave Roussy, 94805 Villejuif Cedex, France; <sup>2</sup>Laboratoire de Réplication de l'ADN et Ultrastructure du Noyau, UPR1983 Institut André Lwoff, 94801 Villejuif Cedex, France

Human Endogenous Retroviruses are expected to be the remnants of ancestral infections of primates by active retroviruses that have thereafter been transmitted in a Mendelian fashion. Here, we derived in silico the sequence of the putative ancestral “progenitor” element of one of the most recently amplified family—the HERV-K family—and constructed it. This element, *Phoenix*, produces viral particles that disclose all of the structural and functional properties of a bona-fide retrovirus, can infect mammalian, including human, cells, and integrate with the exact signature of the presently found endogenous HERV-K progeny. We also show that this element amplifies via an extracellular pathway involving reinfection, at variance with the non-LTR-retrotransposons (LINEs, SINEs) or LTR-retrotransposons, thus recapitulating ex vivo the molecular events responsible for its dissemination in the host genomes. We also show that in vitro recombinations among present-day human *HERV-K* (also known as *ERVK*) loci can similarly generate functional HERV-K elements, indicating that human cells still have the potential to produce infectious retroviruses.

[Supplemental material is available online at [www.genome.org](http://www.genome.org).]

Nearly 8% of the human genome is composed of sequences of retroviral origin. Most of them are degenerate, either due to recombination between the two provirus LTRs or to mutations interrupting the retroviral ORFs. The *env* gene seems to be best conserved, with 18 intact genes retaining a full coding capacity in the human genome (Benit et al. 2001; de Parseval et al. 2003; Villesen et al. 2004), possibly because of its potential role in human physiology. The HERV-K(HML2) family of endogenous retroviruses is an exception to this general rule, since some copies still contain complete ORFs for the other retroviral genes (Löwer et al. 1996; for review, see Bannert and Kurth 2004). This family includes the most recently amplified endogenous retroviruses, most of which have integrated into the genome <5 million years ago, with a few insertions showing polymorphism within the human population (Steinhuber et al. 1995; Medstrand and Mager 1998; Barbulescu et al. 1999; Turner et al. 2001; Hughes and Coffin 2004; Belshaw et al. 2005). Some of these recently integrated proviruses are responsible for the synthesis of retroviral particles that can be observed in teratocarcinoma and melanoma-derived cell lines (Boller et al. 1993; Löwer et al. 1993; Bieda et al. 2001; Muster et al. 2003; Buscher et al. 2005), and possibly in human placenta (Kalter et al. 1973; Dirksen and Levy 1977; Wilkinson et al. 1994). Because of this “activity,” the HERV-K(HML2) family has been the subject of numerous studies in the past years, with the description of alleles with nearly intact

proviruses and complete coding capacity (Mayer et al. 1999; Reus et al. 2001; Turner et al. 2001). Despite these efforts, no functional provirus able to produce infectious particles has yet been described. Even if several loci containing complete ORFs have been identified, and in spite of the availability of the complete sequence of the human genome, the search for a functional provirus is hampered by the significant polymorphism that can be detected at each *HERV-K(HML2)* locus within the human population. To overcome this limitation, we used a reverse strategy and generated a consensus HERV-K(HML2) provirus, thus “resuscitating” *Phoenix*, the likely progenitor of the last, human-specific HERV-K(HML2) amplification burst. This allowed a definite characterization of the structure and life cycle of an “ancestral” retroviral element and recapitulation of the molecular events responsible for its amplification.

## Results

### *Phoenix*, the ancestral HERV-K(HML2) retrovirus

To construct a consensus HERV-K(HML2) provirus, we assembled all of the complete copies of the 9.4-kb proviruses that are human specific (excluding those with the 292-nt deletion at the beginning of the *env* gene) and aligned their nucleotide sequence to generate the consensus in silico, taking for each position the most frequent nucleotide. The resulting provirus sequence contains, as expected, ORFs for all of the HERV-K(HML2)-encoded proteins (Gag, Pro, Pol, Env, and the accessory Rec protein), with *gag*, *pro*, and *pol* separated by –1 frameshifts. Noteworthy, this consensus provirus is distinct from each of the sequences used to generate it, with at least 20 amino acid changes on the overall sequences (Fig. 1).

Based on this in silico reconstruction, we then generated a


<sup>3</sup>Present address: Department of Immunology and Molecular Pathology, University College of London, Windeyer Institute, London W1T 4JF, UK.

<sup>4</sup>These authors contributed equally to this work.

<sup>5</sup>Corresponding author.

E-mail [heidmann@igr.fr](mailto:heidmann@igr.fr); fax 33-1-42-11-53-42.

Article published online before print. Article and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.5565706>.



**Figure 1.** HERV-K(HML2) "endogenization" and present-day human proviruses. (A) Evolutionary scheme for HERV-K(HML2) entry into and invasion of the genome of primates. (B) Map of the full-length 9.4-kb long human-specific HERV-K(HML2) proviruses and comparison with the in silico-engineered consensus sequence. Each provirus is represented by a solid dark line, with the amino acid substitutions in Gag, Pro, Pol, and Env as compared with the consensus element indicated below the line, and the insertions/deletions (ins/ $\Delta$ ) and premature Stop codons (red stars) indicated above the line. The ORF map of the consensus provirus is shown, with *gag* in green, *pro* in pink, *pol* in blue, *env* in orange and yellow, the bipartite *rec* in orange, and the two LTRs as gray boxes. (Note that the first coding exon of *rec* belongs to the *env* ORF). The transcripts responsible for the expression of the viral proteins, with the corresponding spliced out domains (dotted lines), are schematized below the ORF map.

molecular clone corresponding to the consensus DNA proviral sequence that we named *Phoenix*, using the related K108 and K109 proviruses (which we had previously cloned from a commercial human BAC library) as a backbone, and a commercial kit to introduce single nucleotide mutations at each position required to match the consensus. As the HERV-K(HML2) LTRs are not functional in every cell line (Ruda et al. 2004; Lavie et al. 2005), we also replaced the U3 part of the 5' LTR by the CMV


promoter, with its start site positioned so as to conserve the expected nucleotide sequence of the native retroviral transcript. We also introduced a cloning site downstream of the *env* gene into the noncoding U3 region of the 3' LTR to possibly tag (with the *neo* gene) the retroviral transcript without altering its coding capacity.

#### *Phoenix* codes for bona-fide retroviral particles

In a first assay, we introduced the *Phoenix* expression vector into human 293T cells, and looked for retroviral particles by transmission electron microscopy. As illustrated in Figure 2, A and B, this resulted in the synthesis of particles budding from the plasma membrane (not observed with a control vector), as classically observed with  $\gamma$ - (type-C) or  $\delta$ - (HTLV) retroviruses, or even lentiviruses (HIV). No preassembled particles were detected within the cytoplasm, although HERV-K(HML2) elements are more closely related to  $\beta$ - (type-B/D) retroviruses based on their *pol* gene (but this is consistent with viral particle morphology and site of assembly being essentially dependent on the *gag* rather than the *pol* gene). In the extracellular space, two classes of particles could be observed, either with a hollow interior surrounded by a dense ring of stain corresponding to immature particles or with a condensed hexagonal core corresponding most probably to the mature form of the virus (Fig. 2C), in which the polyproteins are cleaved into the final products. Consistently, a provirus with a mutation introduced into the active site of the protease (Pro) also produces particles, but all of them disclose the immature morphology (Fig. 2F). The particles are surrounded by prominent spikes (Fig. 2D) that can be marked in immunoelectron microscopy experiments with an antibody directed against the SU subunit of the HERV-K(HML2) envelope protein (Fig. 2E). As expected, these spikes are absent when the provirus contains a premature Stop codon in the *env* gene (Fig. 2G). Altogether, these features

suggest that *Phoenix* can direct the synthesis of complete retroviral particles.

As a confirmation, we performed immunoblot analyses of the 293T cells transfected with the proviral vector. As illustrated in Figure 3A, *Phoenix*, as well as its *pro* mutant, promotes the synthesis of a Gag precursor of ~80 kDa in cell lysates, as well as some cleaved products (not observed with the *pro* mutant). Cleavage products could also be observed in the supernatant of



**Figure 2.** Electron microscopy of the viral-like particles generated by the *Phoenix* provirus. Human 293T cells were transfected with an expression vector for *Phoenix* (A–E), or mutants (F, G), and observed 48 h post-transfection. (A) Low magnification of particles assembled at the cell membrane. (B) Representative image of particles budding from the plasma membrane. (C) High magnification of two particles, one of which (bottom) discloses a mature (M) morphology with a condensed core, while the other appears to be still immature (IM) with two dark peripheral rings surrounding an electron-lucent core. (D) High magnification of a particle with prominent spikes, corresponding to the Env protein. (E) Image of a particle after labeling with an antibody specific for the HERV-K envelope protein and a secondary antibody linked to gold beads, obtained by immuno-electron microscopy. Quantification of the labeling on 11 independent fields demonstrates association of the gold beads with the viral particles:  $307 \pm 121$  gold beads/ $\mu\text{m}^2$  for the viral particles, versus  $4.9 \pm 3.2$  and  $1.1 \pm 1.5$  gold beads/ $\mu\text{m}^2$  for the cytoplasm and particle-free extracellular space, respectively ( $P < 0.001$  between viral particles and any of the two other compartments, Student's *t*-test). (F) Image of representative particles obtained after transfection with an expression vector for the *Phoenix pro* mutant. All of them disclosed an immature morphology (41 of 41 identified “free” particles, i.e., no more in the budding process, for the *pro* mutant, vs. 15 of 37 for *Phoenix* WT). (G) High magnification of a particle obtained after transfection with an expression vector for the *Phoenix env* mutant. The membrane surrounding the particle is clearly detectable, without any spike. Scale bars: (A): 200 nm, (B–G): 100 nm.


the transfected cells, except for the *pro* mutant that only expresses the Gag precursor. Similarly, using an antibody directed against the SU component of the HERV-K(HML2) envelope protein, we detected, in the supernatants, a protein of a size (55 kDa) consistent with that of the processed SU subunit, but we were unable to detect the Env protein in cell lysates, most probably because of a too-low expression level. Notwithstanding, expression of the envelope protein could be observed by immunofluorescence analysis using HeLa and 293T cells transiently transfected with *Phoenix* (Fig. 3B). In these cells, it can further be observed that Gag and Env colocalize to some common subcellular domains including, as expected, the plasma membrane.

#### *Phoenix* is an infectious retrovirus

To get insight into the functionality of this ancestral virus, we then looked for a reverse-transcriptase activity in the supernatant of the transfected cells. Using the previously described sensitive product-enhanced reverse transcriptase (PERT) assay (Pyra et al. 1994; see Methods), an RT activity could indeed be detected in the supernatant of cells transfected with *Phoenix*, not observed with a provirus in which we had introduced a mutation within the catalytic site of the RT domain (Fig. 3C). To further study the infectivity potential of *Phoenix*-derived particles, we then infected a panel of mammalian cell lines with the supernatant of 293T cells transfected with a *neo*-marked *Phoenix* provirus, and subjected them to G418<sup>R</sup> selection. G418<sup>R</sup> clones were obtained for several target cells including hamster BHK21 cells, feline G355.5 cells, and, noteworthily, the human SH-SY5Y and 293 cells, indicating that *Phoenix* is fully functional and infectious (Fig. 4A). In the same assay, the human HeLa cells and the murine WOP cells seemed to be resistant to infection, most probably due to the absence of the appropriate receptor for the Env protein at the cell surface. We then ensured that the G418<sup>R</sup> clones that were obtained are the result of bona-fide infection. Their occur-

rence actually depends on the presence of intact *gag*, *pro*, *pol*, and *env* genes, since the inactivation of any of the encoded proteins renders *Phoenix* noninfectious without decreasing the amount of viral particles produced, except for the *gag* mutant, as assessed by Western Blot (Fig. 4A; data not shown). In these experiments, the apparent titer of *Phoenix* is quite low even for the cell lines permissive for infection. A quantitative assay by real-time PCR on the genomic DNA from BHK21 cells infected with particles generated by *Phoenix*, marked, or not, by the *neo* gene (see Methods), indicated that the presence of *neo* within the provirus contributes only to a limited extent to this low titer. A possible explanation is that infection with *Phoenix* occurs more efficiently via cell–cell interaction, as observed for HTLV and in some cases HIV (see Discussion), consistent with some images obtained by electron microscopy where budding particles appear to be directly captured by a recipient cell (Fig. 4B).

Next, we characterized further the G418<sup>R</sup> clones that we isolated and determined the provirus insertion sites using an inverse PCR strategy. Identification of the target loci of these new insertions was further asserted by direct PCR reactions between the identified flanking sequences and the *neo* gene of the marked proviruses (see Methods). In all cases, we found complete LTRs with short target-site duplications (TSDs) bordering the newly inserted proviruses (Fig. 5), thus confirming that the infection process is canonical. Rather surprisingly, the TSDs were of a variable length (one of 5 bp and two of 6 bp), which was unexpected since well-characterized retroviral integrases yield TSDs of a fixed length (for review, see Brown 1997). However, our data are consistent with the structures observed for the HERV-K(HML2) endogenous copies of the human genome, since, even if the most common length of the endogenous HERV-K proviruses TSD is 6 bp, we could identify, both in the literature (Barbulescu et al. 1999; Turner et al. 2001) and databases (our unpublished observation), a few elements (three of 15 full-length proviruses) bordered by perfect TSD of only 5 bp (see the endogenous K115




**Figure 3.** Characterization of *Phoenix*. (A) Immunoblot analysis of the *Phoenix* products present in the lysates of transiently transfected 293T cells, or in the concentrated supernatant. Cells were transfected with (1) a control plasmid (pCMV- $\beta$ ), (2) an expression vector for *Phoenix*, or (3) an expression vector for a *pro* mutant. The membranes were hybridized with an antibody directed against the Gag protein (left) or the Env protein (right). (B) Immunofluorescence study of 293T cells transfected with *Phoenix*. Gag is marked in red, Env in green, and the nuclei are stained in blue. Note the colocalization of the two proteins, especially at the membrane that separates the two adjacent marked cells. (C) Detection of RT activity in the concentrated supernatant of 293T cells transfected with *Phoenix* and a series of proviral and control vectors. Concentrated virions were used as a source of RT activity to reverse transcribe synthetic MS2 RNA. Presence of cDNA was revealed via a PCR amplification using appropriate primers. (1) pCMV- $\beta$ ; (2) *Phoenix*; (3) *Phoenix* mutated in RT; (4) chimera K109-K115; (5) chimera K109-K113; (6) chimera K109-K108; (7) MLV core proteins).


provirus in the lower part of Fig. 5 for an illustration). Finally, we mapped the three *Phoenix* insertion sites using the UCSC Genome Browser and found that integration occurred within (for two of three) or close to (<20 kb, for one of three) genes. Although the number of target sites that we characterized is low, and thus cannot reveal subtle insertion site preferences, the identified loci are consistent with the preferences observed for classical retroviruses that favor insertion in transcribed regions (for review, see Bushman 2003). Interestingly, the characterization of the insertion sites of 11 (nearly) full-length HERV-K(HML2) endogenous elements gave a rather different result, with five of them found far from known human genes (>100 kb on each side), four being in the vicinity (<20 kb) of genes, and only two inserted within genes (M. Dewannieux, unpubl.). This discrepancy is probably due to the strong counter-selection that should operate in vivo against insertions within genes, which are most probably deleterious for the proper expression of the targeted genes.

### HERV-K(HML2) provirus amplification via reinfection

Next, to get an insight into the possible physiological mechanism responsible for the amplification of the HERV-K(HML2) family of endogenous retroviruses, we analyzed the relative efficiency of intracellular retrotransposition versus reinfection by *Phoenix*. To do so, we marked *Phoenix* with a specific *neo* indicator gene (*neo*<sup>TNF</sup>), in which *neo* becomes active only after the marked element has been transcribed, reverse-transcribed, and integrated (Esnault et al. 2002). The marked element was introduced by transfection into various cell lines, permissive or not, for infec-



**Figure 4.** Infectious properties of *Phoenix* encoded particles. (A) Infectivity of the HERV-K retroviral particles. The apparent viral titer observed with the *neo*-marked HERV-K(HML2) provirus is indicated for a panel of target cell lines (the quantitative results for the 293 cell line is not shown since their restricted adherence impaired the proper quantification of individual G418<sup>R</sup> clones), together with that obtained with a mutant for the RT domain tested in the same conditions (no clone observed); data are the results from three to eight independent experiments, with the standard deviation indicated. The other mutants (*gag*, *pro*, and *env*) gave the same, negative, results when assayed, with no clone observed in three independent experiments (difference measured between *Phoenix* WT and mutants significant with  $P < 0.001$  for G355.5 and BHK21 cells and  $P < 0.01$  for SH-SY5Y cells, Student's *t*-test). The rationale of the assay is schematized at top. (B) Infection of cells by *Phoenix* particles. On the left, two mature particles appear to interact with the cell membrane of the closest cell, with a thickening of the membrane at the exact point of interaction with the particle. In the middle and on the right, two images suggestive of a cell-to-cell infection are presented, with a particle still budding from its progenitor cell already in contact with the neighboring cell.




**Figure 5.** Structure of three de novo integration sites of *Phoenix* provirus, and comparison with the structure of natural HERV-K provirus insertions. The complete characterization of inserted *Phoenix* elements and insertion sites was performed using individual clones from human SH-SY5Y cells after infection and G418 selection. A provirus insertion and the corresponding empty site are schematized at the top. The sequences of three characterized *Phoenix* de novo insertions are shown below, with the flanking DNA in uppercase and the proviral sequences in lowercase; target-site duplications of 5/6 bp (TSD, yellow) are found in all cases, associated with full-length LTRs. For comparison, the corresponding structures of two resident HERV-K proviruses with a polymorphic insertion in humans (Turner et al. 2001) are presented in the lower part, one with a 5-bp TSD and one with a 6-bp TSD.

tion. Under these conditions, we reproductively obtained G418<sup>R</sup> clones only with the cell lines permissive for infection (i.e., the feline G355.5 cells, the hamster BHK21 cells, and the human SH-SY5Y cells) (Fig. 6; data not shown). This suggests that the amplification process must, at some stage, get the envelope protein receptor involved, and thus should occur via an extracellular reinfection process. To confirm this hypothesis, we performed the same experiment as above, but with the provirus defective for the *env* gene (see Methods), using SH-SY5Y permissive cells. Under these conditions, no amplification of the marked mutant provirus was observed. As a control, addition of a CMV-driven expression vector for the envelope protein restored, at least partially, the mobility of the *env*-defective provirus (Fig. 6) (partial restoration might be due, indirectly, to an identified cytotoxic effect of Env overexpression, as commonly observed with this class of retroviral transmembrane proteins). Altogether, the results strongly support the hypothesis that HERV-K(HML2) amplification in the human genome took place via a reinfection process, possibly in the germ line of the developing embryo, a process consistent both with evolutionary data indicating that the HERV-K(HML2) *env* gene has been subjected to the same purifying selection as the other retroviral genes during amplification of this family (Belshaw et al. 2004) and with the presence

of retroviral particles in human placenta and in germ-line tumors morphologically similar to those produced by *Phoenix* (Kalter et al. 1973; Dirksen and Levy 1977; Boller et al. 1993; Löwer et al. 1993; Wilkinson et al. 1994).

**“Recombination” of human endogenous HERV-K(HML2) loci can generate an infectious retrovirus**

Finally, taking advantage of our present knowledge on the “ancestor” of the HERV-K(HML2) family, we asked whether an “average human genome” would still be able to generate fully infectious retroviral particles. With the proviruses that were used to assemble the consensus sequence, we constructed a set of chimeric elements that could spontaneously emerge via recombination between definite human alleles and were able to express all of the retroviral genes. As described in the Methods, the 5’ part was “borrowed” from the HERV-K109 element, the 3’ end from K108, K113, or K115 (Fig. 7), and the heterologous CMV promoter was introduced, as for *Phoenix*, in place of the U3 part of the 5’ LTR. We assayed these three proviruses for a virion-associated RT activity in the supernatant of human 293T cells following their transient transfection and, remarkably, found that the K109/K115 chimera was positive (Figs. 3C, 7). However, this construct is not infectious on its own, most probably because of defects in the HERV-K115 *env* gene (which is noninfectious in



**Figure 6.** Assay for *Phoenix* “retrotransposition.” (Top) Rationale of the assay. *Phoenix* was marked with the *neo*<sup>TNF</sup> indicator gene for retrotransposition (Esnault et al. 2002), in which *neo* becomes active only after a complete retrotransposition cycle (i.e., transcription, reverse transcription, and integration), and the marked element was introduced by transfection into SH-SY5Y human cells permissive for *Phoenix* infection. The cells were then amplified and subjected to G418 selection for 2 wk; the number of G418<sup>R</sup> clones (several of which were assayed by PCR to demonstrate splicing out of the intron within the *neo* indicator gene) yielded the frequency of retrotransposition of the marked elements. (Bottom) “Retrotransposition” is dependent on the presence of a functional *env* gene, either present within the native *Phoenix* provirus (*Phoenix* WT) or added in *trans* to an *env*-mutated *Phoenix* provirus (*Phoenix* Stop Env) by cotransfection of the cells with an *env* expression vector (CMV Env). The results presented here correspond to three independent experiments, performed with 5–10 × 10<sup>6</sup> cells, and are given as relative transposition frequencies as compared to *neo*<sup>TNF</sup>-marked *Phoenix* (whose transposition frequency is 2 × 10<sup>-5</sup> clone/seeded cell under these conditions).

|                    | RT assay | Infection Assay<br>(arbitrary unit) |
|--------------------|----------|-------------------------------------|
| K108               | —        | < 2                                 |
| K109               | —        | < 2                                 |
| K113               | —        | < 2                                 |
| K115               | —        | < 2                                 |
| K109 / K108        | —        | < 2                                 |
| K109 / K113        | —        | < 2                                 |
| K109 / K115        | +        | < 2                                 |
| K109 / K115 / K108 | +        | 13 ± 1.7                            |
| <i>Phoenix</i>     | +        | 100                                 |

**Figure 7.** An infectious HERV-K(HML2) retrovirus can be generated by in vitro recombination from cloned *HERV-K* loci. Structure of the cloned HERV-K(HML2) proviruses and of the in vitro constructed chimera (see Methods), with the RT activities in the supernatant of 293T cells transfected with the corresponding plasmids measured as in Figure 3C, and the associated infection efficiencies measured by quantitative PCR on the target cell genomic DNA (BHK21 cells, see Methods).

pseudotype experiments, at variance with the K108 *env* gene) (Dewannieux et al. 2005). Therefore we generated a “triple chimera” by replacing the *env* region in the above construct with that from K108 and assayed it for infection. With this element, specific integration of the provirus (i.e., not observed with *Phoenix* mutated in the RT domain used as a control) could be detected in the BHK21 cells by quantitative PCR (see Methods) at a level only five- to 10-fold lower than that observed with *Phoenix* (Fig. 7). This indicates that, as observed in AKR mice where a multistep recombination process reproductively generates new infectious retroviruses (Stoye et al. 1991; Boeke and Stoye 1997), some individuals could reconstitute functional HERV-K(HML2) proviruses either via a three-fragment recombination event, or more likely via a single recombination event between 2 HERV-K copies (e.g., K109 and K115) with complementation in *trans* by an intact envelope protein (e.g., K108). Recombination events have indeed occurred frequently between HERV-K(HML2) proviruses (Hughes and Coffin 2005). In this way, or even using functional (but still uncharacterized) alleles that might be present in some individuals, the HERV-K(HML2) family could repeat its life cycle and regenerate functional elements that could, in turn, be the initiators of amplification events to come.

## Discussion

In the present investigation, the reconstruction of an active HERV-K(HML2) provirus gives access de facto to the first identified human retrovirus of endogenous origin that can consequently be characterized at both the structural and functional level. Actually, following “endogenization,” which transformed its retroviral status into that of a host genomic locus and thus dramatically reduced its evolutionary rate, this element has been frozen in time in its ancestral state, which we have recovered here. The essential attributes of *Phoenix* are those of a type-C retrovirus, with assembly and budding at the cell membrane, release in the cell supernatant of particles disclosing protruding spikes that can be unambiguously identified as envelope proteins, morphological maturation of the core structure upon viral

protease processing, and finally, infectivity of the particles for a range of target cells. Furthermore, analysis of the integrated proviruses associated with infection discloses the specific structural features of retroviral integration, with precise opening of the target sites, insertion of complete proviral structures with reconstituted LTR, and target-site duplications of a few base pairs. Of note, the target-site duplications are not of a fixed length, but vary from 5 to 6 bp. Although this is not common for present-day infectious retroviruses, where the target site duplications are of fixed lengths (for review, see Brown 1997), this peculiarity is also observed for the endogenous proviral *HERV-K* loci, as illustrated in Figure 5. Possibly, this unusual feature might reflect the “age” of *Phoenix* and be a specific characteristic of its ancestral integrase.

Another particular trait of *Phoenix* is its low infectious titer. One possible interpretation could be that this results from its sensitivity to one or more of the multiple cellular defense mechanisms that have evolved to counteract the amplification of retroelements, thus guarding their hosts against the potentially harmful consequences of retrotransposition. The replication of *Phoenix* could be limited by RNA interference-mediated gene silencing, as well as by the action of a variety of host gene-encoded restriction factors, such as members of the AID/APOBEC cytosine deaminase family or of the TRIM protein family (for review, see Goff 2004; Harris and Liddament 2004). Another possible interpretation could be that the still not-identified receptor for this ancestral retrovirus has diverged since its entry into the primate genome and is no more adapted to *Phoenix*, and could even have been positively selected for this divergence for the sake of the host. However, a more likely interpretation, consistent with the frequently observed images shown in Figure 4B, is that its mode of transmission is more closely related to that of retroviruses such as human HTLV, where virions are poorly infectious and spread essentially via cell-cell contacts, most probably at the level of dedicated “virological synapses” (for review, see Jolly and Satten-tau 2004). Similar structures might exist for *Phoenix*, also consistent with its relative phylogenetic proximity to delta- (HTLV) and lenti- (HIV) viruses (Tristem 2000; Benit et al. 2001), and should actually be particularly well suited to optimize cell reinfection and proviral amplification. As a matter of fact, despite its low infectious titer, another important and related outcome of the present investigation is the demonstration that past amplification of *HERV-K* has most probably involved an extracellular pathway and cell reinfection: Indeed, using an appropriate retrotransposition assay, we demonstrate that amplification requires the presence of a functional *env* gene, and is only observed with cells that are permissive for infection. Accordingly, the mode of amplification of *Phoenix* is clearly distinct from that prevailing for most retroelements naturally present in eukaryote genomes, which amplify via a strictly intracellular pathway. These elements include the highly reiterated LINE and SINE sequences, which are non-LTR retrotransposons that replicate also by a copy-and-paste mechanism but are not infectious, and the classical LTR retrotransposons, such as the yeast Ty1 and the *Drosophila copia* elements, which are closely related to retroviruses, of which they are most probably the evolutionary precursors but do not possess an *env* gene and transpose intracellularly (for review, see Boeke and Stoye 1997; Kazazian Jr. 2004; Dewannieux and Heidmann 2005). In this respect, the HERV-K family of elements has a distinct and specific mode of amplification, which very likely also applies to most of the so-called “endogenous retroviruses,” and *Phoenix*, being actually the first infectious

HERV available to date, can therefore be considered as a model element to characterize the life cycle of these invaders of all mammalian genomes.

Finally, the present active cloned element provides a potent tool to appraise the role of elements of the HERV-K family in a range of diseases where related particles and viral proteins have been detected. These include essentially, but not exclusively, human tumors such as germ-line tumors and melanomas, where such elements have been suggested to play a role (Boller et al. 1993; Löwer et al. 1993, 1996; Bieda et al. 2001; Muster et al. 2003; Buscher et al. 2005) (for review, see Bannert and Kurth 2004). Taking into account their retroviral origin, firmly established by the present investigation, it is indeed legitimate to hypothesize that HERV-K elements have conserved some of the pathological potency of infectious retroviruses, which could arise upon their transcriptional activation. Clearly, most present-day infectious retroviruses are pathogenic and mediate such effects via both insertional mutagenesis and the activity of the viral proteins they encode. The present study clearly shows that *Phoenix* is a complex retrovirus that can insert into new genomic locations, and that most probably, human cells can generate active retroviruses by recombination between genomic loci. As shown in the Results section, in vitro recombination between cloned HERV-K copies indeed generate a functional element (and active when further placed under the control of the strong CMV promoter) and it is likely, taking into account the polymorphism of such elements in the human population, that some alleles might still be functional and even become fully active in some definite circumstances. Search for such alleles, possibly among individuals with specific tumors where HERV-K elements are expressed and viral particles detected, should now be performed using *Phoenix* as a functional "reference" element together with the presently devised infectivity assay.

Altogether, the present results have allowed the structural and functional characterization of the oldest active retrovirus isolated to date and the unraveling of the molecular scenario responsible for its successful amplification in primate genomes. They also provide tools for elucidating the role of its "genomic offspring" in human diseases, in particular in some tumors that have primarily been qualified as of genetic origin, but could ultimately turn out to have a bona-fide retroviral basis. In this respect, this study also suggests that more appropriate safety conditions should be considered for the manipulation of such tissues and tumor cell lines.

## Methods

### In silico engineering and in vitro reconstruction of the HERV-K(HML2) consensus provirus

To generate the consensus HERV-K(HML2) provirus sequence, we took the nucleotide sequences of the nine full-length, human-specific, 9.4-kb class proviruses that can be found in sequence databases and publications and aligned them using ClustalW to generate the consensus sequence (see Supplemental Fig. 1; Supplemental Table 1). To obtain a backbone for the *Phoenix* provirus expression vector, we subcloned the K108 and K109 proviruses by digesting commercial BAC clones RP11-33P21 and RP11-152J15 (BACPAC Resources), and generated chimeric constructs to get closer to the consensus sequence. Fragments from these chimeric constructs were placed in pALTER-1 plasmid (Promega) and subjected to successive rounds of site-directed mutagenesis using the Altered Sites II in vitro Mutagenesis System

(Promega) and appropriate primers. When all expected mutations had been introduced, the *Phoenix* provirus was reassembled in the pBluescript plasmid and we checked the whole construct by sequencing. To generate the CMV expression vector, the CMV promoter region was isolated from pCMV $\beta$  (Clontech, EcoRI-SacI fragment) and used it to replace the U3 part of the 5' LTR, using PCR, so as to keep the transcription start site unchanged.

Point mutations within the protease and RT motifs (from LVDTGA to LVaaaA and from YIDD to aIaa, respectively) were introduced using the Altered Sites II in vitro Mutagenesis System (Promega) and appropriate primers. Inactivation of the *gag* gene was achieved via an in-phase deletion between the SfoI and PshAI unique sites, and the *env* gene was disrupted by inserting a small synthetic linker containing Stop codons in all six frames at the unique StuI site (located at the end of the SU subunit, position 7784 in the sequence provided in Supplemental Fig. 1).

This series of expression vectors was marked with the *SV neo* resistance gene or *SV neo<sup>TNF</sup>* retrotransposition indicator gene by inserting fragments taken from pSVneo\* and pSVneo<sup>TNF</sup> plasmids (Esnault et al. 2002), respectively, at position 8662 of the consensus sequence (position according to the sequence provided in Supplemental Fig. 1).

### Construction of chimeric HERV-K proviruses

To generate the chimeric HERV-K proviruses, we first constructed an expression vector for the HERV-K109 copy by replacing the U3 part of its 5' LTR by the CMV promoter region. The 3' part of this provirus was replaced by the corresponding sequences of K113 and K115 proviruses (from the unique SexAI site to the end) or K108-1 (from the SacI site to the end). For the triple chimera K109-K115-K108, the 3' domain of K109-K115 was replaced by the corresponding part of the K108-1 provirus (from the XbaI site to the end).

### Production of antibodies: Western blot analysis and immunofluorescence studies

We developed a polyclonal anti-HERV-K Gag antiserum by immunizing rabbits with a mix of purified recombinant proteins produced in bacteria, covering the complete HERV-K113 Gag protein. The resulting sera were checked by Immunoblot analyses and affinity-purified before use (Agrobio). The monoclonal antibody directed against the SU subunit of the HERV-K envelope protein has already been described (Dewannieux et al. 2005). We also raised a rabbit antiserum specific for the HERV-K envelope protein using a recombinant protein produced in bacteria, corresponding to aa 223–437 of the K109 Env protein.

For analysis of retroviral protein expression and cleavage, 293T cells transiently transfected with the provirus expression vectors (using Lipofectamine and +Reagent; Invitrogen) were lysed in Laemmli buffer 48 h post-transfection and lysate proteins directly separated by SDS-PAGE, followed by transfer onto nitrocellulose membranes (Schleicher and Schuell) and incubation with the appropriate antibody and with a secondary antibody linked to Horseradish peroxidase. For analysis of cell supernatants, 293T cells were transfected by the Calcium Phosphate method using the MBS commercial kit (Stratagene). Particulate material in the medium was concentrated by ultracentrifugation on a 20% sucrose cushion 48 h post-transfection, and the virions were lysed in Laemmli buffer before viral protein analysis by SDS-PAGE and immunoblotting.

Immunofluorescence analysis of the intracellular localization of Gag and Env was carried out on 293T cells transiently transfected with the *Phoenix* expression vector. Cells were fixed 30 h post-transfection, permeabilized, and stained with a rabbit

polyclonal anti-Gag serum and a mouse monoclonal anti-Env antibody. Alexa 546-conjugated goat anti-rabbit IgG and Alexa 488-conjugated goat anti-mouse IgG were used as secondary antibodies (Molecular Probes); nuclei were stained with Dapi and Topro3 (Molecular Probes).

### Electron microscopy

For morphological studies, cells were fixed in phosphate buffer (pH 7.2), 3% glutaraldehyde for 1 h, and post-fixed in 0.1 M cacodylate buffer, 1% osmium tetroxide for 2 h. After being rinsed for 5 min in water and 15 min in 0.1 M cacodylate buffer, cells were transferred to 0.2 M cacodylate buffer for 30 min. Cells were washed in 30% methanol for 10 min, stained in 2% uranyl acetate in 0.1 M cacodylate buffer, 30% methanol for 1 h, and washed in 30% methanol. Cells were then dehydrated through a graded ethanol-propylene oxide series and embedded in Epon 812. Ultrathin sections were collected on formvar-carbon-coated gold grids (200-mesh), stained with 4% uranyl acetate and lead citrate, and examined with a Zeiss 902 microscope at 80 Kv.

For immuno-electron microscopy experiments, transfected cells were fixed for 1 h at 4°C with either 4% formaldehyde or 1.6% glutaraldehyde in 0.1 M phosphate buffer (pH 7.3). During fixation, the cells were scraped from the plates and centrifuged. Pellets were dehydrated in increasing concentrations of methanol and embedded in Lowicryl K4M at low temperature. Polymerization was carried out for 5 d at -30°C under long-wavelength UV light. Ultrathin sections of Lowicryl-embedded material were collected on formvar-carbon-coated gold grids (200-mesh) and used for labeling with a rabbit antiserum specific for the SU subunit of the HERV-K envelope protein, followed by incubation with a goat anti-rabbit IgG conjugated to gold particles, 10 nm in diameter. Sections were contrasted as above. The specificity of the association between the gold beads and the viral particles was performed by counting, in 11 independent fields, the number of gold particles/ $\mu\text{m}^2$  within three "compartments" (viral particles, cytoplasm, and particle-free extracellular space).

### RT assay

Assays for the presence of RT activity in cell supernatants were performed using transiently transfected 293T cells. At day 2 post-transfection, the medium was harvested, filtered through 0.45- $\mu\text{m}$  pore-sized membranes, and particulate material concentrated by ultracentrifugation on a 20% sucrose cushion. The virions were lysed in Buffer A (25 mM Tris, 0.25 mM EDTA, 50 mM KCl, 5 mM DTT, 0.025% Triton X-100, 50% glycerol) and used as a reverse-transcriptase source for reverse transcription of commercial MS2 RNA (adapted from the PERT assay described in Pyra et al. 1994). Briefly, 300 ng of MS2 RNA were annealed to 16 pmol of RT-1 primer and incubated with viral lysate corresponding to 1–2 mL of cell supernatant. cDNA synthesis was then assayed using 1/25 of the RT reaction as a template for a 25 cycle PCR reaction conducted with RT-1 and RT-2 primers (Pyra et al. 1994). In these assays, expression vectors for the MLV and HIV core proteins were used as positive controls and CMV- $\beta$  (Clontech) as a negative control.

### Infection and retrotransposition assays

For infection assays, 293T cells were used as producer cells, following transient transfection with the consensus provirus by the Calcium Phosphate method (Stratagene MBS commercial kit). Target cell lines (SH-SY5Y, BHK21, G355.5, HeLa, and WOP) were seeded the day before infection in 6-well plates. The day of infection, the supernatants of 293T cells were harvested, filtered through 0.45- $\mu\text{m}$  pore-sized membranes, and added to target

cells (1 mL per well, with 4  $\mu\text{g}/\text{mL}$  polybrene). To increase the sensitivity of the assay, the target cells were then subjected to "spinoculation" (centrifugation at 1200g for 2.5 h) and incubated overnight at 37°C before medium change. For detection of infection events, target cells were split into 10-cm plates ( $\sim 5 \times 10^5$  cells per plate) at day 3 post infection and subjected to G418 selection 24 h later. For infection assays using quantitative PCR,  $10^5$  BHK21 cells were seeded in 6-well plates and used as target cells. At day 2 post-infection, the cells were washed with DNaseI to remove residual DNA and split, and genomic DNA was recovered at days 5–6 post-infection. DNA purification was performed via two successive phenol/chloroform extractions followed by ethanol precipitation. Integration events were detected with the Taqman technology using a 5'-FAM MGB probe (6FAM-ATAGTGTATGGGTACCTGGC-MGBNFQ, Applied Biosystems) and primers specific for the HERV-K(HML2) family (5'-GCCTTTCCC GCCCTTAATT-3' and 5'-GCAGGGCAGCGATCATCTA-3'), and 500 ng of genomic DNA as a template. The infectious titers were estimated by comparison with a standard obtained by mixing genomic DNAs extracted from naive BHK21 cells and from a clone containing a single inserted provirus in varying proportions. In this assay, the titer of Phoenix WT was in the  $10^3$  infectious particles/milliliter range. BHK21 cells were chosen as the target cell line, since their genomic DNA generates only very limited background with the HERV-K-specific primers and probe used in this assay; genomic DNA of BHK21 cells infected with Phoenix particles deficient for the RT was used as a negative control to rule out contamination by residual DNA that could originate from the transfected plasmid or genomic DNA of the producer cells.

For retrotransposition assays,  $7.5 \times 10^5$  SH-SY5Y cells were seeded in 60-mm dishes the day prior to transfection. Transfection was performed using 8  $\mu\text{L}$  of Plus Reagent (Invitrogen), 12  $\mu\text{L}$  of Lipofectamine (Invitrogen), and 3  $\mu\text{g}$  of DNA (2.5  $\mu\text{g}$  of Phoenix-derived expression vector and 0.5  $\mu\text{g}$  of *env* expression plasmid or control plasmid). Cells were grown for 1 wk before plating on 10-cm plates and subsequent selection with G418. The results presented here correspond to three independent experiments performed with  $5\text{--}10 \times 10^6$  cells and are given as relative transposition frequencies as compared with *neo*<sup>TNF</sup>-marked Phoenix (whose absolute transposition frequency is  $2 \times 10^{-5}$  clone/seeded cell under these conditions).

### Characterization of HERV-K(HML2) de novo insertion sites

Integration sites were analyzed by inverse PCR using individual G418<sup>R</sup> clones essentially as described (Dewannieux et al. 2003). Briefly, 5  $\mu\text{g}$  of DNA from each clone was digested with PvuII and either (1) DraI, (2) SspI, or (3) with a mix of XbaI, AvrII, and SpeI, or (4) with ApoI alone. After enzyme removal, DNA was diluted and self-ligated overnight. It was ethanol-precipitated, dissolved in 20  $\mu\text{L}$  of Tris 10 mM, and subjected to one (or in some cases two) round of PCR with sets of divergent primers located within the *neo* gene and designed for the amplification of the 5' or 3' end and flanking sequences of the newly inserted proviruses. The amplified DNAs were gel-purified, cloned, and sequenced, thus yielding the target-site sequences. The identification of these insertion sites was further confirmed by PCR reactions allowing direct amplification of both left and right junctions between the newly inserted proviruses and the identified loci, using for each reaction a primer specific for the identified insertion locus and an internal primer located in the *neo* gene. In each case, we checked that the same reactions performed on the naive, noninfected target cells did not yield any specific amplification. Primer sequences are available on request.



## Safety precautions

All manipulations involving the reconstructed HERV-K were carried out in our lab according to the rules established by the "Commission de Génie Génétique" from the "Ministère délégué à l'Enseignement supérieur et à la Recherche" French authority that regulates handling of genetically modified organisms in all research institutions in France.

Albeit the HERV-K virus has a very low infectivity and does not sustain multiple-cycle infection, at least in all the cells tested, *Phoenix* is a retrovirus, and as such, is a priori eligible to BL3 conditions for manipulation. Accordingly, the material will only be sent to other labs in appropriate sealed containers in the form of small amounts of plasmid DNA that will require it to be amplified before use as a transfection vector to produce viral particles. At the present time and as a precautionary principle, it will only be distributed under a material transfer agreement specifying the commitment of the recipient labs to carry out every experiment using the material under BL3 conditions and accompanied by a duly signed authorization form from the Biosafety Committee responsible for genetic manipulations in their country of origin.

## Acknowledgments

We thank A. Jalil for assistance with confocal microscopy, E. Pichard for technical assistance, and C. Lavialle for critical reading of the manuscript. This work was supported by the CNRS and by grants from the Ligue Nationale contre Le Cancer (Equipe Labellisée).

## References

Bannert, N. and Kurth, R. 2004. Retroelements and the human genome: New perspectives on an old relation. *Proc. Natl. Acad. Sci.* **101**: 14572–14579.

Barbulescu, M., Turner, G., Seaman, M.I., Deinard, A.S., Kidd, K.K., and Lenz, J. 1999. Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. *Curr. Biol.* **9**: 861–868.

Belshaw, R., Pereira, V., Katzourakis, A., Talbot, G., Paces, J., Burt, A., and Tristem, M. 2004. Long-term reinfection of the human genome by endogenous retroviruses. *Proc. Natl. Acad. Sci.* **25**: 25.

Belshaw, R., Dawson, A.L., Woolven-Allen, J., Redding, J., Burt, A., and Tristem, M. 2005. Genomewide screening reveals high levels of insertional polymorphism in the human endogenous retrovirus family HERV-K(HML2): Implications for present-day activity. *J. Virol.* **79**: 12507–12514.

Benit, L., Dessen, P., and Heidmann, T. 2001. Identification, phylogeny, and evolution of retroviral elements based on their envelope genes. *J. Virol.* **75**: 11709–11719.

Bieda, K., Hoffmann, A., and Boller, K. 2001. Phenotypic heterogeneity of human endogenous retrovirus particles produced by teratocarcinoma cell lines. *J. Gen. Virol.* **82**: 591–596.

Boeke, J.D. and Stoye, J.P. 1997. Retrotransposons, endogenous retroviruses, and the evolution of retroelements. In *Retroviruses* (eds. J.M. Coffin et al.), pp. 343–435. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Boller, K., König, H., Sauter, M., Mueller-Lantzsch, N., Löwer, R., Löwer, J., and Kurth, R. 1993. Evidence that HERV-K is the endogenous retrovirus sequence that codes for the human teratocarcinoma-derived retrovirus HTDV. *Virology* **196**: 349–353.

Brown, P.O. 1997. Integration. In *Retroviruses* (eds. J.M. Coffin et al.), pp. 161–204. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Buscher, K., Trefzer, U., Hofmann, M., Sterry, W., Kurth, R., and Denner, J. 2005. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. *Cancer Res.* **65**: 4172–4180.

Bushman, F.D. 2003. Targeting survival. Integration site selection by retroviruses and LTR-retrotransposons. *Cell* **115**: 135–138.

de Parseval, N., Lazar, V., Bénit, L., Casella, J., and Heidmann, T. 2003. Survey of human genes of retroviral origin: Identification and transcriptome of the genes with coding capacity for complete envelope proteins. *J. Virol.* **77**: 10414–10422.

Dewannieux, M. and Heidmann, T. 2005. LINEs, SINEs and processed pseudogenes: Parasitic strategies for genome modeling. *Cytogenet. Genome Res.* **110**: 35–48.

Dewannieux, M., Esnault, C., and Heidmann, T. 2003. LINE-mediated retrotransposition of marked *Alu* sequences. *Nat. Genet.* **35**: 41–48.

Dewannieux, M., Blaise, S., and Heidmann, T. 2005. Identification of a functional envelope protein from the HERV-K family of human endogenous retroviruses. *J. Virol.* **79**: 15573–15577.

Dirksen, E. and Levy, J. 1977. Virus-like particles in placentas from normal individuals and patients with systemic lupus erythematosus. *J. Natl. Cancer Inst.* **59**: 1187–1192.

Esnault, C., Casella, J.F., and Heidmann, T. 2002. A Tetrahymena thermophila ribozyme-based indicator gene to detect transposition of marked retroelements in mammalian cells. *Nucleic Acids Res.* **30**: e49.

Goff, S. 2004. Retrovirus restriction factors. *Mol. Cell* **16**: 849–859.

Harris, R.S. and Liddament, M.T. 2004. Retroviral restriction by APOBEC proteins. *Nat. Rev. Immunol.* **4**: 868–877.

Hughes, J.F. and Coffin, J.M. 2004. Human endogenous retrovirus K solo-LTR formation and insertional polymorphisms: Implications for human and viral evolution. *Proc. Natl. Acad. Sci.* **101**: 1668–1672.

Hughes, J.F. and Coffin, J.M. 2005. Human endogenous retroviral elements as indicators of ectopic recombination events in the primate genome. *Genetics* **12**: 12.

Jolly, C. and Sattentau, Q.J. 2004. Retroviral spread by induction of virological synapses. *Traffic* **5**: 643–650.

Kalter, S.S., Helmke, R.J., Heberling, R.L., Panigel, M., Fowler, A.K., Strickland, J.E., and Hellman, A. 1973. C-Type particles in normal human placentas. *J. Natl. Cancer Inst.* **50**: 1081–1084.

Kazazian Jr., H.H. 2004. Mobile elements: Drivers of genome evolution. *Science* **303**: 1626–1632.

Lavie, L., Kitova, M., Maldener, E., Meese, E., and Mayer, J. 2005. CpG methylation directly regulates transcriptional activity of the human endogenous retrovirus family HERV-K(HML-2). *J. Virol.* **79**: 876–883.

Löwer, R., Boller, K., Hasenmaier, B., Korbmacher, C., Mueller-Lantzsch, N., Löwer, J., and Kurth, R. 1993. Identification of human endogenous retroviruses with complex mRNA expression and particle formation. *Proc. Natl. Acad. Sci.* **90**: 4480–4484.

Löwer, R., Löwer, J., and Kurth, R. 1996. The viruses in all of us: Characteristics and biological significance of human endogenous retrovirus sequences. *Proc. Natl. Acad. Sci.* **93**: 5177–5184.

Mayer, J., Sauter, M., Racz, A., Scherer, D., Mueller-Lantzsch, N., and Meese, E. 1999. An almost-intact human endogenous retrovirus K on human chromosome 7. *Nat. Genet.* **21**: 257–258.

Medstrand, P. and Mager, D.L. 1998. Human-specific integrations of the HERV-K endogenous retrovirus family. *J. Virol.* **72**: 9782–9787.

Muster, T., Waltenberger, A., Grassauer, A., Hirschl, S., Caucig, P., Romirer, I., Fodinger, D., Seppel, H., Schanab, O., Magin-Lachmann, C., et al. 2003. An endogenous retrovirus derived from human melanoma cells. *Cancer Res.* **63**: 8735–8741.

Pyra, H., Boni, J., and Schupbach, J. 1994. Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product enhancement. *Proc. Natl. Acad. Sci.* **91**: 1544–1548.

Reus, K., Mayer, J., Sauter, M., Scherer, D., Muller-Lantzsch, N., and Meese, E. 2001. Genomic organization of the human endogenous retrovirus HERV-K(HML-2.HOM) (ERV6) on chromosome 7. *Genomics* **72**: 314–320.

Ruda, V.M., Akopov, S.B., Trubetskoy, D.O., Manuylov, N.L., Vetchinova, A.S., Zavalova, L.L., Nikolaev, L.G., and Sverdlov, E.D. 2004. Tissue specificity of enhancer and promoter activities of a HERV-K(HML-2) LTR. *Virus Res.* **104**: 11–16.

Steinhuber, S., Brack, M., Hunsmann, G., Schwelberger, H., Dierich, M.P., and Vogetseder, W. 1995. Distribution of human endogenous retrovirus HERV-K genomes in humans and different primates. *Hum. Genet.* **96**: 188–192.

Stoye, J.P., Moroni, C., and Coffin, J.M. 1991. Virological events leading to spontaneous AKR thymomas. *J. Virol.* **65**: 1273–1285.

Tristem, M. 2000. Identification and characterization of novel human endogenous retrovirus families by phylogenetic screening of the human genome mapping project database. *J. Virol.* **74**: 3715–3730.

Turner, G., Barbulescu, M., Su, M., Jensen-Seaman, M.I., Kidd, K.K., and Lenz, J. 2001. Insertional polymorphisms of full-length endogenous retroviruses in humans. *Curr. Biol.* **11**: 1531–1535.

Villesen, P., Aagaard, L., Wiuf, C., and Pedersen, F.S. 2004. Identification of endogenous retroviral reading frames in the human genome. *Retrovirology* **1**: 32.

Wilkinson, D.A., Mager, D.L., and Leong, J.A.C. 1994. Endogenous human retroviruses. In *The retroviridae* (ed. J.A. Levy), pp. 465–535. Plenum Press, New York.

Received May 28, 2006; accepted in revised form August 30, 2006.